NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 11:48
Last Report Issued 01/27/2017 09:55

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1055SP
Patient ID 1055SP
Chain 17000126
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 17000126

Received 01/27/2017 09:54

Sample ID 17000126-001
Matrix Serum or Plasma
Patient Name 1055SP
Patient ID 1055SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
1055SP Celecoxib, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Celecoxib	None Detected	ng/mL	20	
Synonym(s): Celebrex®				
Single oral doses of 100 and 200 mg in 4 subjects resulted in average peak plasma concentrations of 362 and 797 ng/mL, respectively, at times of 1.4 and 1.8 hours. Elimination half-lives in rapid and slow metabolizers averaged 14 and 52 hours, respectively.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.